Doug Williams’ Codiak Biosciences gets $61M Series B for exosome work
This closes out Codiak Biosciences' Series B round first announced alongside its November launch - bringing the fledgling startup's funding to $92 million.
This closes out Codiak Biosciences' Series B round first announced alongside its November launch - bringing the fledgling startup's funding to $92 million.
Former Biogen R&D chief Doug Williams is launching a biotech startup called Codiak BioSciences with $80 million. It is developing exosomes as a new diagnostic and therapeutic tool, beginning with pancreatic cancer.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.